Skip to main content
SpringerLink
Log in

The action and mechanism of myrislignan on A549 cells in vitro and in vivo

  • Original Paper
  • Published:
Journal of Natural Medicines Aims and scope Submit manuscript

Abstract

Myrislignan is a natural compound with little pharmacological study. In our investigation, we investigated the effect of myrislignan in the induction of apoptosis in A549 cells in vitro and in vivo. Myrislignan inhibited the proliferation of A549 cells in a dose- and time-dependent manner assayed by MTT. In addition, Hoechst flow cytometry showed that myrislignan significantly induced apoptosis and cell cycle arrest in A549 cells. The apoptosis and anti-cell proliferation was mediated by the activation of mitogen-activated protein kinase and the inhibition of epidermal growth factor receptor signal pathway, change of mitochondrial membrane potential, the releasing of c-Myc, the downregulation of the level of the anti-apoptotic protein Bcl-2, and the upregulation of the level of the pro-apoptotic protein Bax. In conclusion, those results reveal a potential mechanism for the anti-cancer effect of myrislignan on human lung cancer, while suggesting that myrislignan may be a promising compound for the treatment of lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wang Y, Sun Y (2015) Clinical experiences with molecular targeted therapy in lung cancer in China. Thorac Cancer 6(4):379–384

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Johnson DH, Schiller JH, Bunn PA Jr (2014) Recent clinical advances in lung cancer management. J Clin Oncol 32(10):973–982

    Article  CAS  PubMed  Google Scholar 

  3. DeSantis C, Naishadham D, Jemal A (2013) Cancer statistics for African Americans, 2013. CA Cancer J Clin 63(3):151–166

    Article  PubMed  Google Scholar 

  4. Spira A, Halmos B, Powell CA (2015) Update in lung cancer 2014. Am J Respir Crit Care Med 192(3):283–294

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA (2014) Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 85(2):101–109

    Article  PubMed  PubMed Central  Google Scholar 

  6. Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer 121(5):664–672

    Article  CAS  PubMed  Google Scholar 

  7. Suda K, Sato K, Mizuuchi H, Kobayashi Y, Shimoji M, Tomizawa K, Takemoto T, Iwasaki T, Sakaguchi M, Mitsudomi T (2014) Recent evidence, advances, and current practices in surgical treatment of lung cancer. Respir Investig 52(6):322–329

    Article  PubMed  Google Scholar 

  8. Badr CE, Van Hoppe S, Dumbuya H, Tjon-Kon-Fat LA, Tannous BA (2013) Targeting cancer cells with the natural compound obtusaquinone. J Natl Cancer Inst 105(9):643–653

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Yang XW, Huang X, Ahmat M (2008) New neolignan from seed of Myristica fragrans. Zhongguo Zhong Yao Za Zhi 33(4):397–402

    CAS  PubMed  Google Scholar 

  10. Li F, Yang XW (2008) Quantification of myrislignan in rat plasma by solid-phase extraction and reversed-phase high-performance liquid chromatography. Biomed Chromatogr 22(6):601–605

    Article  CAS  PubMed  Google Scholar 

  11. Du SS, Yang K, Wang CF, You CX, Geng ZF, Guo SS, Deng ZW, Liu ZL (2014) Chemical constituents and activities of the essential oil from Myristica fragrans against cigarette beetle Lasioderma serricorne. Chem Biodivers 11(9):1449–1456

    Article  CAS  PubMed  Google Scholar 

  12. Cao GY, Xu W, Yang XW, Gonzalez FJ, Li F (2015) New neolignans from the seeds of Myristica fragrans that inhibit nitric oxide production. Food Chem 173:231–237

    Article  CAS  PubMed  Google Scholar 

  13. Li F, Yang XW (2008) Biotransformation of myrislignan by rat liver microsomes in vitro. Phytochemistry 69(3):765–771

    Article  CAS  PubMed  Google Scholar 

  14. Jin H, Zhu ZG, Yu PJ, Wang GF, Zhang JY, Li JR, Ai RT, Li ZH, Tian YX, Zhang WX, Wu SG (2012) Myrislignan attenuates lipopolysaccharide-induced inflammation reaction in murine macrophage cells through inhibition of NF-kappaB signalling pathway activation. Phytother Res 26(9):1320–1326

    Article  CAS  PubMed  Google Scholar 

  15. Yang XW, Huang X, Ma L, Wu Q, Xu W (2010) The intestinal permeability of neolignans from the seeds of Myristica fragrans in the Caco-2 cell monolayer model. Planta Med 76(14):1587–1591

    Article  CAS  PubMed  Google Scholar 

  16. Wang Y, Liu JX, Zhang YB, Li F, Yang XW (2012) Determination and distribution study of myrislignan in rat tissues by RP-HPLC. Chromatographia 75:541–549

    Article  CAS  Google Scholar 

  17. Chen Z, Huang X, Yang H, Ding W, Gao L, Ye Z, Zhang Y, Yu Y, Lou Y (2011) Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo. Chem Biol Interact 189(1–2):90–99

    Article  CAS  PubMed  Google Scholar 

  18. Estaquier J, Vallette F, Vayssiere JL, Mignotte B (2012) The mitochondrial pathways of apoptosis. Adv Exp Med Biol 942:157–183

    Article  CAS  PubMed  Google Scholar 

  19. Morabito A, Carillio G, Daniele G, Piccirillo MC, Montanino A, Costanzo R, Sandomenico C, Giordano P, Normanno N, Perrone F, Rocco G, Di Maio M (2014) Treatment of small cell lung cancer. Crit Rev Oncol Hematol 91(3):257–270

    Article  PubMed  Google Scholar 

  20. Chaveli-López B (2014) Oral toxicity produced by chemotherapy: a systematic review. J Clin Exp Dent 6(1):e81–e90

    Article  PubMed  PubMed Central  Google Scholar 

  21. Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, Gong J, Zhong Z, Xu Z, Dang Y, Guo J, Chen X, Wang Y (2011) Anti-cancer natural products isolated from Chinese medicinal herbs. Chin Med 6(1):27

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Himeji M, Ohtsuki T, Fukazawa H, Tanaka M, Yazaki S, Ui S, Nishio K, Yamamoto H, Tasaka K, Mimura A (2007) Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell. Cancer Lett 245(1–2):269–274

    Article  CAS  PubMed  Google Scholar 

  23. Griffin C, Karnik A, McNulty J, Pandey S (2011) Pancratistatin selectively targets cancer cell mitochondria and reduces growth of human colon tumor xenografts. Mol Cancer Ther 10(1):57–68

    Article  CAS  PubMed  Google Scholar 

  24. Kalemkerian GP (2014) Advances in pharmacotherapy of small cell lung cancer. Expert Opin Pharmacother 15(16):2385–2396

    Article  CAS  PubMed  Google Scholar 

  25. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51(5):1417–1423

    Article  CAS  PubMed  Google Scholar 

  26. Lurje G, Lenz HJ (2009) EGFR signaling and drug discovery. Oncology 77(6):400–410

    Article  CAS  PubMed  Google Scholar 

  27. Uribe P, Gonzalez S (2011) Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract 207(6):337–342

    Article  CAS  PubMed  Google Scholar 

  28. Bai Y, Yu W, Han N, Yang F, Sun Y, Zhang L, Zhao M, Huang L, Zhou A, Wang F, Li X (2013) Effects of semaphorin 3A on retinal pigment epithelial cell activity. Invest Ophthalmol Vis Sci 54(10):6628–6638

    Article  CAS  PubMed  Google Scholar 

  29. Kuroda S, Tam J, Roth JA, Sokolov K, Ramesh R (2014) EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomed 9:3825–3839

    CAS  Google Scholar 

  30. Lee H, Lee H, Chin H, Kim K, Lee D (2014) ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. Oncotarget 5(13):5138–5152

    Article  PubMed  PubMed Central  Google Scholar 

  31. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792

    Article  CAS  PubMed  Google Scholar 

  32. Huguet F, Fernet M, Giocanti N, Favaudon V, Larsen AK (2016) Afatinib, an irreversible EGFR family inhibitor, shows activity toward pancreatic cancer cells, alone and in combination with radiotherapy, independent of KRAS status. Target Oncol 11(3):371–381

    Article  PubMed  Google Scholar 

  33. Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang XQ, Cai WM (2015) Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Acta Pharmacol Sin 36(5):614–626

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Normanno N, Campiglio M, Maiello MR, De Luca A, Mancino M, Gallo M, D’Alessio A, Menard S (2008) Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Res Treat 112(1):25–33

    Article  CAS  PubMed  Google Scholar 

  35. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26(22):3279–3290

    Article  CAS  PubMed  Google Scholar 

  36. Burova EB, Smirnova IS, Gonchar IV, Shatrova AN, Nikolsky NN (2011) Inhibition of the EGF receptor and ERK1/2 signaling pathways rescues the human epidermoid carcinoma A431 cells from IFNgamma-induced apoptosis. Cell Cycle 10(13):2197–2205

    Article  CAS  PubMed  Google Scholar 

  37. Xu T, Wang NS, Fu LL, Ye CY, Yu SQ, Mei CL (2012) Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. Mol Biol Rep 39(7):7743–7753

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zhang XJ, Zhang L, Liu YP, Xu HM, Sun P, Song JG, Luo YH (2013) Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway. Zhonghua Zhong Liu Za Zhi 35(3):181–186

    PubMed  Google Scholar 

  39. Jiang Y, Zhang Y, Luan J, Duan H, Zhang F, Yagasaki K, Zhang G (2010) Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology 62(6):573–583

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ashkenazi A, Salvesen G (2014) Regulated cell death: signaling and mechanisms. Annu Rev Cell Dev Biol 30:337–356

    Article  CAS  PubMed  Google Scholar 

  41. Green DR, Llambi F (2015) Cell death signaling. Cold Spring Harb Perspect Biol 7(12). pii: a006080

  42. Li L, Gao Y, Zhang L, Zeng J, He D, Sun Y (2008) Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett 272(1):61–69

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Financial support for this research was provided by State Administration of Traditional Chinese Medicine “Twelfth Five Year Plan” Key Specialty (Chinese Medicine Geriatrics). Technological support for this research was provided by Shanghai Key Laboratory of Clinical Geriatric Medicine.

Author information

Author notes

    Authors and Affiliations

    1. Department of Traditional Chinese Medicine, HuaDong Hospital, FuDan University, Shanghai, 200040, People’s Republic of China

      XinGang Lu & HongFu Qiu

    2. Department of Tumor, BaoShan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 201999, People’s Republic of China

      Liu Yang

    3. Department of Traditional Chinese Medicine, RuiJin Hospital, JiaoTong University School of Medicine, Shanghai, 200025, People’s Republic of China

      JingXian Chen

    4. Department of Pulmonary, HuaDong Hospital, FuDan University, Shanghai, 200040, People’s Republic of China

      JiAn Zhou, XiaoDan Tang & YingGang Zhu

    5. Department of Pharmacy, HuaDong Hospital, FuDan University, No. 221, West YanAn Rd, Shanghai, 200040, People’s Republic of China

      Jie Shen

    Authors
    1. XinGang Lu
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Liu Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. JingXian Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. JiAn Zhou
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. XiaoDan Tang
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. YingGang Zhu
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. HongFu Qiu
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Jie Shen
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Jie Shen.

    Ethics declarations

    Conflict of interest

    No potential conflicts of interest were disclosed.

    Additional information

    X. Lu and L. Yang contributed to this work equally.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    11418_2016_1029_MOESM1_ESM.tif

    Supplementary Fig. 1. Myrislignan induced apoptosis and cell cycle arrest in A549 cells. Flow cytometry assay was used to determine the apoptosis of A549 cells with increasing concentrations of myrislignan or combined with EGF (100 ng/ml) for 48 h. a Annexin-V/PI assay. b Cell cycle assay. Statistical differences were considered significant at the levels of *p < 0.05, **p < 0.01, or ***p < 0.001

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Lu, X., Yang, L., Chen, J. et al. The action and mechanism of myrislignan on A549 cells in vitro and in vivo. J Nat Med 71, 76–85 (2017). https://doi.org/10.1007/s11418-016-1029-6

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s11418-016-1029-6

    Keywords

    Search

    Navigation